New research identifies a mechanism of action for the GLP-1 receptor, the target of GLP-1 diabetes drugs Research led by Imperial has uncovered a hidden cellular mechanism that explains how widely used type 2 diabetes drugs signal to protect the pancreas, opening up new possibilities for improving future diabetes therapies
10.1016/j.stem.2009.02.013 63
Route of Administration Insights The oral segment dominated the market with a revenue share of 51.19%, owing to growing innovation in pill and capsule formulations that enhance absorption and minimize gastrointestinal side effects
Adequate protein intake helps preserve lean muscle mass during weight loss
Key Points: In people with T2D and obesity, increasing semaglutide beyond 2 mg per week results in modest improvements in glycaemic control and greater weight loss, but also significantly more gastrointestinal adverse events
Patients sometimes skip therapy because of nausea, medication costs, supply shortages, or unrealistic expectations regarding results
